Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.
about
The gut hormones in appetite regulationThe intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directionsInflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.Glucagon-like peptide-2 regulates release of chylomicrons from the intestine.Emerging treatment options for short bowel syndrome: potential role of teduglutideUmami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in miceEffect of glucagon-like peptide 2 on hepatic, renal, and intestinal disposition of 1-chloro-2,4-dinitrobenzeneMechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblastsIrinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.Microbial translocation across the GI tractDisruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritisA pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patientsThe therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.The "cryptic" mechanism of action of glucagon-like peptide-2.Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors.Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.Review article: a comparison of glucagon-like peptides 1 and 2.The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.Teduglutide in Crohn's disease.Systemic immune activation in HIV and potential therapeutic options.Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease.Integrated Neural and Endocrine Control of Gastrointestinal Function.Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.Plasma citrulline as surrogate marker of intestinal inflammation in pediatric and adolescent with Crohn's disease: preliminary report.Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer.Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats.Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration.Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer.The gut as a sensory organ.Rate and Predictors of Endoscopic Mucosal Healing in Biologic Naive Patients with Inflammatory Bowel Disease by Azathioprine Treatment: A Real World, 10 Years' Experience from a Single Centre in Turkey.Glucagon like peptide-2 and neoplasia; a systematic review.Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model.The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha/actinomycin D.
P2860
Q21296779-21F3621A-2E25-4051-8EEA-71A1754482B5Q26745700-5CAB4D74-985B-4C2B-BE08-9A6FF882EAE5Q26752511-47844BED-50B6-43D9-97B7-93519013A7A2Q34494154-441607CD-6124-43F3-808C-5A90C6F3F65BQ35046115-B881AF87-B24B-474D-AD54-B190E83577F1Q35304614-903CF4EC-24C1-4331-952D-ECE1D36C1957Q35429613-DFB269DA-6AC5-480B-BF0C-D768339595F9Q35986076-34882272-E711-4349-BE51-EE7AFBDE172CQ36057404-E5251395-37E2-4C22-9AE5-1FF35430B2E2Q36063090-805E1F13-5843-4382-A0EB-B9802B3E222AQ36171894-F69456BD-F865-4BBF-AE0A-EF0BD8C9D872Q36309586-68059F01-CC5D-4DF7-91E7-D4F88C7038F2Q36441742-9C46346E-9009-44DD-BFA1-4D0ED1939F3BQ36710034-1AB8CAEF-B245-4903-8A14-7C9CAA9C2E6AQ37247764-DED2CE2D-AED1-4143-8BEA-5FEEB1025838Q37840099-98999E31-EA91-408F-A5BC-E44D937BDF63Q37870031-852DE174-9265-43F4-9446-BC445ADB44CAQ37975414-10080CEB-00EF-4E17-BC76-C6EA19DA33C5Q38048602-64C3429A-0B14-48DE-9202-322D51CD7841Q38057350-2F46A4D8-3E37-4E74-B1FC-1E029A93FDD4Q38101129-A599B4FA-5794-47F2-BD0D-808445749385Q38120028-7EBF9910-4EE5-4D4E-A4F2-AA24788A138CQ38189500-6D42B47E-3CEB-487D-A81A-D3CCCA09A208Q38542147-FC1D4979-58AA-4BE0-B488-31FA151F5505Q38886433-83D3244C-D665-4DA1-A3B3-B2452C0E0582Q39585744-1A5E4D31-BDAE-4AB8-BC8A-5230D092DA60Q39739606-C8639740-590C-4967-836A-8A9A34FD59F8Q42721362-FE64748B-17A9-42B2-9834-2371410F646BQ42943394-11C974C6-B99D-4F94-9702-22CBEB52832BQ43168687-168E8C11-24FC-4063-92BE-99F84EC06893Q45216920-267A647D-E932-438B-9F67-88C2DC50A6BBQ45894561-80B326C3-BB01-464F-A872-D82D0AD5DE03Q46938538-FD3D3269-1717-477F-BD98-8C958DCC973FQ49901206-A9219A2F-A476-474A-AC8F-F430D2307412Q51830867-BC53B3BA-2AEA-4DAC-8C34-023AABB1201AQ53283425-BEF140F8-8351-4229-A174-1ED23E214FF7
P2860
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.
@en
Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.
@nl
type
label
Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.
@en
Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.
@nl
prefLabel
Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.
@en
Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.
@nl
P2093
P2860
P356
P1476
Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.
@en
P2093
Alan L Buchman
Charles N Bernstein
John C Fang
Seymour Katz
Souheil G Abou-Assi
Teduglutide Study Group
P2860
P304
P356
10.1002/IBD.21117
P577
2010-06-01T00:00:00Z